119 related articles for article (PubMed ID: 16828609)
1. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study.
Al-Shaer MH; Jerome WP
Am J Cardiol; 2006 Jul; 98(2):275-6. PubMed ID: 16828609
[No Abstract] [Full Text] [Related]
2. Combination therapy in the management of mixed dyslipidaemia.
Cannon CP
J Intern Med; 2008 Apr; 263(4):353-65. PubMed ID: 18324928
[TBL] [Abstract][Full Text] [Related]
3. Management of the metabolic syndrome-nicotinic acid.
Meyers CD; Kashyap ML
Endocrinol Metab Clin North Am; 2004 Sep; 33(3):557-75, vii. PubMed ID: 15262297
[TBL] [Abstract][Full Text] [Related]
4. On the road to better dyslipidemia outcomes.
Hughes S
Nurse Pract; 2009 Feb; 34(2):14-21; quiz 22. PubMed ID: 19155874
[No Abstract] [Full Text] [Related]
5. Metabolic syndrome, diabetes and coronary heart disease.
Haffner SM
Int J Clin Pract Suppl; 2002 Oct; (132):31-7. PubMed ID: 12425361
[No Abstract] [Full Text] [Related]
6. Treatment of the dyslipidemia of insulin resistance.
Smith DA
Med Clin North Am; 2007 Nov; 91(6):1185-210, x. PubMed ID: 17964916
[TBL] [Abstract][Full Text] [Related]
7. Lipid screening and cardiovascular health in childhood.
Daniels SR; Greer FR;
Pediatrics; 2008 Jul; 122(1):198-208. PubMed ID: 18596007
[TBL] [Abstract][Full Text] [Related]
8. Dyslipidaemia in diabetic patients: time for a rethink.
Shepherd J
Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
[TBL] [Abstract][Full Text] [Related]
9. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
[No Abstract] [Full Text] [Related]
10. [Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
Cybulska B; Kłosiewicz-Latoszek L
Kardiol Pol; 2005 Jun; 62 Suppl 2():II45-50. PubMed ID: 19813336
[No Abstract] [Full Text] [Related]
11. Treating dyslipidemia of the metabolic syndrome: where's the evidence?
Eckel RH
Nat Clin Pract Endocrinol Metab; 2007 Jun; 3(6):437. PubMed ID: 17515887
[No Abstract] [Full Text] [Related]
12. [Therapy of dyslipidemia in post-infarction: state of the art].
Borgia MC; Nardi M; Da Ros S; Castellano V
Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
[TBL] [Abstract][Full Text] [Related]
13. FIELD study.
Rees A
Diabet Med; 2006 Jul; 23 Suppl 3():6-12. PubMed ID: 16805876
[No Abstract] [Full Text] [Related]
14. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
15. Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia.
Hu S; Shearer GC; Steffes MW; Harris WS; Bostom AG
Am J Kidney Dis; 2011 Jan; 57(1):181-2. PubMed ID: 20888102
[No Abstract] [Full Text] [Related]
16. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
17. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction.
Davidson MH; Ballantyne CM
Am J Cardiol; 2008 Apr; 101(8A):1B-2B. PubMed ID: 18375235
[No Abstract] [Full Text] [Related]
18. Lipid management in children.
Zappalla FR; Gidding SS
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):171-83. PubMed ID: 19217518
[TBL] [Abstract][Full Text] [Related]
19. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
20. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
